RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and ...
Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), likely contributing to the persistent inflammation characteristic of the ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM ...
Tiziana Life Sciences announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) who were treated with intranasal foralumab, a ...
The International Progressive MS Alliance announces the launch of its MS Clinical and Imaging Data Resource (CIDR), which provides the academic and research community access to anonymized and ...
A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...
Hosted on MSN
Pacing, planning, and prioritizing: Must-know energy-management secrets for progressive MS
Fatigue is one of the most common and challenging symptoms for people living with primary-progressive and secondary-progressive multiple sclerosis (MS). It affects physical stamina, mental clarity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results